Marcus Gutmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcus Gutmann has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Tessa Lühmann
Institute for Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany
11 shared publications - Lorenz Meinel
Institute for Pharmacy and Food Chemistry, University of Würzburg, Würzburg, Germany
10 shared publications Lukas Hahn
Institute of Pharmacy and Food Chemistry
6 shared publications- Josef Kehrein
Institute for Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, Würzburg, Germany, 97074
4 shared publications Martina Raschig
Institute of Pharmacy and Food Chemistry
4 shared publications- Alena Maria Wolkersdorfer
Institute of Pharmacy and Food Chemistry
3 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by American Chemical Society (ACS) in ChemRxiv
A shared formulation design space reveals poly(2-ethyl-2oxazoline) chain length as a determinant of lipid nanoparticle performance and relative organ distribution
The interface between lipid nanoparticles (LNPs) and their biological environment represents a key determinant of biodistribution. Here, we investigated poly(2-ethyl-2oxazoline) (PEtOx)-lipids as an adaptable component of this interface and determined how polymer chain length affects LNP formulation as well as biological behavior. Rather than comparing different polymers with a single nominal formulation composition, we first mapped the pharmaceutical design space of four PEtOx-lipids containing average chain lengths of 20, 34, 49, or 71 repeating units and identified formulation conditions that supported acceptable LNP formation. This shared design space subsequently enabled the comparison of chain-length-dependent effects under pharmaceutically viable conditions. Increasing PEtOx chain length decreased the apparent hydrophobicity of the PEtOx-lipids and was associated with progressively smaller LNP diameters, lower mRNA encapsulation efficiencies, and a narrower formulation space in which predefined criteria for size, polydispersity, and mRNA loading were met concomitantly. Optimized PEtOx-LNPs mediated mRNA expression across multiple primary and human induced pluripotent stem cell-derived cell types with limited effects on cell viability. Pooled in vivo DNA barcoding of the PEtOx20-, PEtOx34-, and PEtOx49-LNPs revealed chain-length-dependent differences in relative organ barcode distribution, with shorter chains shifting relative distribution toward spleen and pancreas and away from bone marrow and liver. Together, these findings establish PEtOx chain length as an independent LNP design parameter and demonstrate a formulation-space-based strategy for comparing polymeric excipients without relying on a single predefined formulation composition.
- 17 November 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA shared formulation design space reveals poly(2-ethyl-2oxazoline) chain length as a determinant of lipid nanoparticle performance and relative organ distribution
The interface between lipid nanoparticles (LNPs) and their biological environment represents a key determinant of biodistribution. Here, we investigated poly(2-ethyl-2oxazoline) (PEtOx)-lipids as an adaptable component of this interface and determined how polymer chain length affects LNP formulation as well as biological behavior. Rather than comparing different polymers with a single nominal formulation composition, we first mapped the pharmaceutical design space of four PEtOx-lipids containing average chain lengths of 20, 34, 49, or 71 repeating units and identified formulation conditions that supported acceptable LNP formation. This shared design space subsequently enabled the comparison of chain-length-dependent effects under pharmaceutically viable conditions. Increasing PEtOx chain length decreased the apparent hydrophobicity of the PEtOx-lipids and was associated with progressively smaller LNP diameters, lower mRNA encapsulation efficiencies, and a narrower formulation space in which predefined criteria for size, polydispersity, and mRNA loading were met concomitantly. Optimized PEtOx-LNPs mediated mRNA expression across multiple primary and human induced pluripotent stem cell-derived cell types with limited effects on cell viability. Pooled in vivo DNA barcoding of the PEtOx20-, PEtOx34-, and PEtOx49-LNPs revealed chain-length-dependent differences in relative organ barcode distribution, with shorter chains shifting relative distribution toward spleen and pancreas and away from bone marrow and liver. Together, these findings establish PEtOx chain length as an independent LNP design parameter and demonstrate a formulation-space-based strategy for comparing polymeric excipients without relying on a single predefined formulation composition.
- Open Access
- 9 August 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Programming Lipid Nanoparticle Interfaces through Function-Encoded Statistical Polymers
Poly(ethylene glycol) (PEG) is the standard stealth polymer to functionalize lipid nanoparticle (LNP) surfaces, requiring conjugation to a lipid tail for anchoring in the LNP’s shell. We eliminate the need for lipid conjugates by introducing a new polymer-only design principle using function-encoded statistical polymers. For that, we synthesized statistical amphiphilic copolymers in which hydrophobic units are followed by hydrophilic units, with the intention that the hydrophobic units of the polymer anchor to the LNP surface, and its hydrophilic parts stealth the particle surface. We screened the formulation space using a 42-member poly(2-oxazoline) library, yielding design rules for successful LNP formulations. Cryogenic transmission electron microscopy confirmed the intact LNP structure, and biological activity was assessed in multiple human cell types differentiated from inducible pluripotent stem cells. Intravenously administered barcoded LNPs formulated with function-encoded statistical polymers compared to the equivalent PEG-lipid LNPs showed 2.5- and 5-fold higher amounts in mice and lower bloodstream levels, leading to significantly higher accumulation in the spleen and liver. Rather than assembling LNP interfaces from multiple molecular components, this work establishes that orthogonal interfacial functions can be encoded directly into the architecture of a single statistical polymer, providing a general molecular design principle for programmable nanomedicine interfaces.
- 9 August 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessProgramming Lipid Nanoparticle Interfaces through Function-Encoded Statistical Polymers
Poly(ethylene glycol) (PEG) is the standard stealth polymer to functionalize lipid nanoparticle (LNP) surfaces, requiring conjugation to a lipid tail for anchoring in the LNP’s shell. We eliminate the need for lipid conjugates by introducing a new polymer-only design principle using function-encoded statistical polymers. For that, we synthesized statistical amphiphilic copolymers in which hydrophobic units are followed by hydrophilic units, with the intention that the hydrophobic units of the polymer anchor to the LNP surface, and its hydrophilic parts stealth the particle surface. We screened the formulation space using a 42-member poly(2-oxazoline) library, yielding design rules for successful LNP formulations. Cryogenic transmission electron microscopy confirmed the intact LNP structure, and biological activity was assessed in multiple human cell types differentiated from inducible pluripotent stem cells. Intravenously administered barcoded LNPs formulated with function-encoded statistical polymers compared to the equivalent PEG-lipid LNPs showed 2.5- and 5-fold higher amounts in mice and lower bloodstream levels, leading to significantly higher accumulation in the spleen and liver. Rather than assembling LNP interfaces from multiple molecular components, this work establishes that orthogonal interfacial functions can be encoded directly into the architecture of a single statistical polymer, providing a general molecular design principle for programmable nanomedicine interfaces.
- Open Access
- 1 October 2025
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 11 (11) , 2172-2179
A Viral Neuraminidase-Specific Sensor for Taste-Based Detection of Influenza
Influenza has caused the deadliest pandemics in history, thereby prompting advances in our ability to ensure vigilance at all stages of future outbreaks. Quarantining patients early is crucial when it comes to preventing these outbreaks, but it is challenging with influenza due to presymptomatic transmission. Presymptomatic detection translates into massive screening needs, which necessitate cost-effective tools with access for anyone, anywhere, and at any time. We met these challenges by synthesizing sensors that respond to influenza infections with taste generation by using the tongue as an always-available detector. In doing so, we utilized the virus’s need for neuraminidase cleavage of α-glycosidic bonds to detect its presence in patients. We synthesized N-acetylneuraminic acid-thymol derivatives and chemically tuned them to respond to viral but not bacterial neuraminidase. Viral selectivity was further confirmed via structural analysis and molecular docking. Influenza sensors that respond to viral presence with taste may have unmatched advantages regarding accessibility and cost-effectiveness, including the potential to first-line stratify millions of healthy individuals from flu patients, thereby enabling us to leverage our response armamentarium in future outbreaks.
- 1 October 2025
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 11 (11) , 2172-2179
Open AccessA Viral Neuraminidase-Specific Sensor for Taste-Based Detection of Influenza
Influenza has caused the deadliest pandemics in history, thereby prompting advances in our ability to ensure vigilance at all stages of future outbreaks. Quarantining patients early is crucial when it comes to preventing these outbreaks, but it is challenging with influenza due to presymptomatic transmission. Presymptomatic detection translates into massive screening needs, which necessitate cost-effective tools with access for anyone, anywhere, and at any time. We met these challenges by synthesizing sensors that respond to influenza infections with taste generation by using the tongue as an always-available detector. In doing so, we utilized the virus’s need for neuraminidase cleavage of α-glycosidic bonds to detect its presence in patients. We synthesized N-acetylneuraminic acid-thymol derivatives and chemically tuned them to respond to viral but not bacterial neuraminidase. Viral selectivity was further confirmed via structural analysis and molecular docking. Influenza sensors that respond to viral presence with taste may have unmatched advantages regarding accessibility and cost-effectiveness, including the potential to first-line stratify millions of healthy individuals from flu patients, thereby enabling us to leverage our response armamentarium in future outbreaks.
- 14 February 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (3) , 1253-1261
Designing the Aplysia punctata Arginine-Depleting Enzyme for Tumor Targeting
L-Amino acid oxidases (LAAO) deaminate amino acids to α-keto acids and generate hydrogen peroxide, a reactive oxygen species (ROS) with potential value for cancer therapy. We recombinantly expressed the LAAO from Aplysia punctata, called APIT (Cuvier 1803). The resulting wild-type APIT (APITwt) was conjugated to polyethylene glycol (APIT-PEG). Furthermore, an APIT mutant with an affibody targeting the human epidermal growth factor receptor 2 (HER2; zHER2-APIT) was genetically engineered resulting in a binding affinity KD of ∼ 2.2 nM to the HER2 receptor ectodomain. Further, we evaluated if the APIT and tumor-targeted APIT can be used as an APIT-drug conjugate by covalently amidating the lysine residues on the protein surface. However, for the HER2-targeted APIT, the affibody contains lysines as well, and amidation of these lysines could have impaired the affibody's affinity to the HER2 receptor. Therefore, we designed a lysine-free variant of the tumor-targeting part of zHER2-APIT using an in silico mutation analysis, suggesting the replacement of the lysines of the affibody by arginine or alanine. This new variant is referred to as zHER2(K-del)-APIT. To simulate a covalent drug loading to APIT and the targeting constructs, we attached biotin by amidation. Biotin-zHER2(K-del)-APIT successfully allowed binding to HER2-positive but not HER2-negative cells in vitro. The biodistribution of these novel constructs was tested in xenografted mice with a HER2-positive and negative tumor in each animal. The zHER2(K-del)-APIT lost its ability to target HER2-positive tumors despite the in vitro data suggesting otherwise. The zHER2-APIT accumulated within the HER2-positive tumors but not in the negative tumors. APIT-PEG had increased uptake in HER2-positive and negative tumors compared to APITwt, which can be attributed to a prolonged serum half-life achieved by PEGylation, due to the absence of any tumor-targeting effect. These biodistribution studies point to HER2-targeting LAAOs for cancer therapy and PEGylation increasing tumor accumulation.
- 14 February 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (3) , 1253-1261
Designing the Aplysia punctata Arginine-Depleting Enzyme for Tumor Targeting
L-Amino acid oxidases (LAAO) deaminate amino acids to α-keto acids and generate hydrogen peroxide, a reactive oxygen species (ROS) with potential value for cancer therapy. We recombinantly expressed the LAAO from Aplysia punctata, called APIT (Cuvier 1803). The resulting wild-type APIT (APITwt) was conjugated to polyethylene glycol (APIT-PEG). Furthermore, an APIT mutant with an affibody targeting the human epidermal growth factor receptor 2 (HER2; zHER2-APIT) was genetically engineered resulting in a binding affinity KD of ∼ 2.2 nM to the HER2 receptor ectodomain. Further, we evaluated if the APIT and tumor-targeted APIT can be used as an APIT-drug conjugate by covalently amidating the lysine residues on the protein surface. However, for the HER2-targeted APIT, the affibody contains lysines as well, and amidation of these lysines could have impaired the affibody's affinity to the HER2 receptor. Therefore, we designed a lysine-free variant of the tumor-targeting part of zHER2-APIT using an in silico mutation analysis, suggesting the replacement of the lysines of the affibody by arginine or alanine. This new variant is referred to as zHER2(K-del)-APIT. To simulate a covalent drug loading to APIT and the targeting constructs, we attached biotin by amidation. Biotin-zHER2(K-del)-APIT successfully allowed binding to HER2-positive but not HER2-negative cells in vitro. The biodistribution of these novel constructs was tested in xenografted mice with a HER2-positive and negative tumor in each animal. The zHER2(K-del)-APIT lost its ability to target HER2-positive tumors despite the in vitro data suggesting otherwise. The zHER2-APIT accumulated within the HER2-positive tumors but not in the negative tumors. APIT-PEG had increased uptake in HER2-positive and negative tumors compared to APITwt, which can be attributed to a prolonged serum half-life achieved by PEGylation, due to the absence of any tumor-targeting effect. These biodistribution studies point to HER2-targeting LAAOs for cancer therapy and PEGylation increasing tumor accumulation.
- Open Access
- 9 May 2024
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 10 (6) , 3825-3832
PEGylated Recombinant Aplysia punctata Ink Toxin Depletes Arginine and Lysine and Inhibits the Growth of Tumor Xenografts
In recent years, a novel treatment method for cancer has emerged, which is based on the starvation of tumors of amino acids like arginine. The deprivation of arginine in serum is based on enzymatic degradation and can be realized by arginine deaminases like the l-amino acid oxidase found in the ink toxin of the sea hare Aplysia punctata. Previously isolated from the ink, the l-amino acid oxidase was described to oxidate the essential amino acids l-lysine and l-arginine to their corresponding deaminated alpha-keto acids. Here, we present the recombinant production and functionalization of the amino acid oxidase Aplysia punctata ink toxin (APIT). PEGylated APIT (APIT–PEG) increased the blood circulation time. APIT–PEG treatment of patient-derived xenografted mice shows a significant dose-dependent reduction of tumor growth over time mediated by amino acid starvation of the tumor. Treatment of mice with APIT–PEG, which led to deprivation of arginine, was well tolerated.
- 9 May 2024
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 10 (6) , 3825-3832
Open AccessPEGylated Recombinant Aplysia punctata Ink Toxin Depletes Arginine and Lysine and Inhibits the Growth of Tumor Xenografts
In recent years, a novel treatment method for cancer has emerged, which is based on the starvation of tumors of amino acids like arginine. The deprivation of arginine in serum is based on enzymatic degradation and can be realized by arginine deaminases like the l-amino acid oxidase found in the ink toxin of the sea hare Aplysia punctata. Previously isolated from the ink, the l-amino acid oxidase was described to oxidate the essential amino acids l-lysine and l-arginine to their corresponding deaminated alpha-keto acids. Here, we present the recombinant production and functionalization of the amino acid oxidase Aplysia punctata ink toxin (APIT). PEGylated APIT (APIT–PEG) increased the blood circulation time. APIT–PEG treatment of patient-derived xenografted mice shows a significant dose-dependent reduction of tumor growth over time mediated by amino acid starvation of the tumor. Treatment of mice with APIT–PEG, which led to deprivation of arginine, was well tolerated.
- 21 November 2023
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 10 (1) , 156-165
Matrix Metalloproteinase-Responsive Delivery of PEGylated Fibroblast Growth Factor 2
Attachment of polyethylene glycol (PEG) chains is a common, well-studied, and Food and Drug Administration-approved method to address the pharmacokinetic challenges of therapeutic proteins. Occasionally, PEGylation impairs the activity of pharmacodynamics (PD). To overcome this problem, disease-relevant cleavable linkers between the polymer and the therapeutic protein can unleash full PD by de-PEGylating the protein at its target site. In this study, we engineered a matrix metalloproteinase (MMP)-responsive fibroblast growth factor 2 (FGF-2) mutant that was site-specifically extended with a PEG polymer chain. Using bioinspired strategies, the bioconjugate was designed to release the native protein at the desired structure/environment with preservation of the proliferative capacity in vitro on NIH3T3 cells. In vivo, hepatic exposure was diminished but not its renal distribution over time compared to unconjugated FGF-2. By releasing the growth factor from the PEG polymer in response to MMP cleavage, restored FGF-2 may enter hard-to-reach tissues and activate cell surface receptors or nuclear targets.
- 21 November 2023
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 10 (1) , 156-165
Matrix Metalloproteinase-Responsive Delivery of PEGylated Fibroblast Growth Factor 2
Attachment of polyethylene glycol (PEG) chains is a common, well-studied, and Food and Drug Administration-approved method to address the pharmacokinetic challenges of therapeutic proteins. Occasionally, PEGylation impairs the activity of pharmacodynamics (PD). To overcome this problem, disease-relevant cleavable linkers between the polymer and the therapeutic protein can unleash full PD by de-PEGylating the protein at its target site. In this study, we engineered a matrix metalloproteinase (MMP)-responsive fibroblast growth factor 2 (FGF-2) mutant that was site-specifically extended with a PEG polymer chain. Using bioinspired strategies, the bioconjugate was designed to release the native protein at the desired structure/environment with preservation of the proliferative capacity in vitro on NIH3T3 cells. In vivo, hepatic exposure was diminished but not its renal distribution over time compared to unconjugated FGF-2. By releasing the growth factor from the PEG polymer in response to MMP cleavage, restored FGF-2 may enter hard-to-reach tissues and activate cell surface receptors or nuclear targets.
- 9 June 2023
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 10 (1) , 149-155
PEGylation of Human Vascular Endothelial Growth Factor
Vascular endothelial growth factor A-165 (VEGF-A165) positively modulates neointimal hyperplasia, lumen stenosis, and neovascularization. One challenge for the use of VEGF-A165 for potential therapy is its short serum half-life. Therefore, we are designing VEGF-A165 bioconjugates carrying polyethylene glycol (PEG). The purity of the recombinantly expressed human VEGF-A165 exceeded 90%. The growth factor had a half-maximal effective concentration of 0.9 ng/mL (EC50) and induced tube formation of human umbilical vein endothelial cells. PEGylation was conducted by Schiff base reaction followed by reductive amination. After purification, two species were obtained, with one or two PEG attached per VEGF-A165 dimer. Both resulting bioconjugates had a purity exceeding 90%, wild-type bioactivity, and increased hydrodynamic radii as required for prolonging the half-life.
- 9 June 2023
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 10 (1) , 149-155
PEGylation of Human Vascular Endothelial Growth Factor
Vascular endothelial growth factor A-165 (VEGF-A165) positively modulates neointimal hyperplasia, lumen stenosis, and neovascularization. One challenge for the use of VEGF-A165 for potential therapy is its short serum half-life. Therefore, we are designing VEGF-A165 bioconjugates carrying polyethylene glycol (PEG). The purity of the recombinantly expressed human VEGF-A165 exceeded 90%. The growth factor had a half-maximal effective concentration of 0.9 ng/mL (EC50) and induced tube formation of human umbilical vein endothelial cells. PEGylation was conducted by Schiff base reaction followed by reductive amination. After purification, two species were obtained, with one or two PEG attached per VEGF-A165 dimer. Both resulting bioconjugates had a purity exceeding 90%, wild-type bioactivity, and increased hydrodynamic radii as required for prolonging the half-life.
- 29 November 2022
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 9 (6) , 2937-2948
Oral Use of Therapeutic Carbon Monoxide for Anyone, Anywhere, and Anytime
Carbon monoxide (CO) is a therapeutic gas with therapeutic potential in intestinal bowel disease. Therapeutic efficacy in the gastrointestinal tract (GIT) must be paired with safe and convenient use. Therefore, we designed an oral CO releasing system (OCORS) pairing tunable CO release into the GIT while preventing the release of any other molecule from within the device, causing safety concerns. The dimensions of the device, which is manufactured from 3D printed components, are within compendial limits. This is achieved by controlling CO decarbonylation from a molybdenum complex with a FeCl3 solution. OCORS' surrounding silicon membranes control release rates, as does the loading with carbonylated molybdenum complex and FeCl3 solution. Herein we describe the development of the system, the characterization of the CO releasing molecule (CORM), and the CO release kinetics of the overall system. Neither the CORM nor isocyanoacetate as a potential reaction byproduct were cytotoxic. Finally, we demonstrated by design validation in an in vivo porcine model that, except for the release of the therapeutic CO, OCORS isolates all components during transit through the stomach. We could show that OCORS generated and released CO locally into the stomach of the animals without systemic exposure, measured as the carboxyhemoglobin content in the blood of the pigs. In conclusion, OCORS derisks oral development by limiting patient exposure to (desirable) CO while preventing contact with any further (undesirable) chemical, by-, or degradation products. CO generating devices come in reach, which now can be used by anyone, anywhere, and anytime.
- 29 November 2022
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 9 (6) , 2937-2948
Oral Use of Therapeutic Carbon Monoxide for Anyone, Anywhere, and Anytime
Carbon monoxide (CO) is a therapeutic gas with therapeutic potential in intestinal bowel disease. Therapeutic efficacy in the gastrointestinal tract (GIT) must be paired with safe and convenient use. Therefore, we designed an oral CO releasing system (OCORS) pairing tunable CO release into the GIT while preventing the release of any other molecule from within the device, causing safety concerns. The dimensions of the device, which is manufactured from 3D printed components, are within compendial limits. This is achieved by controlling CO decarbonylation from a molybdenum complex with a FeCl3 solution. OCORS' surrounding silicon membranes control release rates, as does the loading with carbonylated molybdenum complex and FeCl3 solution. Herein we describe the development of the system, the characterization of the CO releasing molecule (CORM), and the CO release kinetics of the overall system. Neither the CORM nor isocyanoacetate as a potential reaction byproduct were cytotoxic. Finally, we demonstrated by design validation in an in vivo porcine model that, except for the release of the therapeutic CO, OCORS isolates all components during transit through the stomach. We could show that OCORS generated and released CO locally into the stomach of the animals without systemic exposure, measured as the carboxyhemoglobin content in the blood of the pigs. In conclusion, OCORS derisks oral development by limiting patient exposure to (desirable) CO while preventing contact with any further (undesirable) chemical, by-, or degradation products. CO generating devices come in reach, which now can be used by anyone, anywhere, and anytime.
- Open Access
- 27 May 2022
- Published by Wiley in Chemistry – A European Journal
- Vol. 28 (39) , e202200786
Synthesis and Biological Evaluation of Flavonoid‐Cinnamic Acid Amide Hybrids with Distinct Activity against Neurodegeneration in Vitro and in Vivo
Flavonoids are polyphenolic natural products and have shown significant potential as disease‐modifying agents against neurodegenerative disorders like Alzheimer's disease (AD), with activities even in vivo. Hybridization of the natural products taxifolin and silibinin with cinnamic acid led to an overadditive effect of these compounds in several phenotypic screening assays related to neurodegeneration and AD. Therefore, we have exchanged the flavonoid part of the hybrids with different flavonoids, which show higher efficacy than taxifolin or silibinin, to improve the activity of the respective hybrids. Chemical connection between the flavonoid and cinnamic acid was realized by an amide instead of a labile ester bond to improve stability towards hydrolysis. To investigate the influence of a double bond at the C‐ring of the flavonoid, the dehydro analogues of the respective hybrids were also synthesized. All compounds obtained show neuroprotection against oxytosis, ferroptosis and ATP‐depletion, respectively, in the murine hippocampal cell line HT22. Interestingly, the taxifolin and the quercetin derivatives are the most active compounds, whereby the quercetin derivate shows even more pronounced activity than the taxifolin one in all assays applied. As aimed for, no hydrolysis product was found in cellular uptake experiments after 4 h whereas different metabolites were detected. Furthermore, the quercetin‐cinnamic acid amide showed pronounced activity in an in vivo AD mouse model at a remarkably low dose of 0.3 mg/kg.
- 27 May 2022
- Published by Wiley in Chemistry – A European Journal
- Vol. 28 (39) , e202200786
Open AccessSynthesis and Biological Evaluation of Flavonoid‐Cinnamic Acid Amide Hybrids with Distinct Activity against Neurodegeneration in Vitro and in Vivo
Flavonoids are polyphenolic natural products and have shown significant potential as disease‐modifying agents against neurodegenerative disorders like Alzheimer's disease (AD), with activities even in vivo. Hybridization of the natural products taxifolin and silibinin with cinnamic acid led to an overadditive effect of these compounds in several phenotypic screening assays related to neurodegeneration and AD. Therefore, we have exchanged the flavonoid part of the hybrids with different flavonoids, which show higher efficacy than taxifolin or silibinin, to improve the activity of the respective hybrids. Chemical connection between the flavonoid and cinnamic acid was realized by an amide instead of a labile ester bond to improve stability towards hydrolysis. To investigate the influence of a double bond at the C‐ring of the flavonoid, the dehydro analogues of the respective hybrids were also synthesized. All compounds obtained show neuroprotection against oxytosis, ferroptosis and ATP‐depletion, respectively, in the murine hippocampal cell line HT22. Interestingly, the taxifolin and the quercetin derivatives are the most active compounds, whereby the quercetin derivate shows even more pronounced activity than the taxifolin one in all assays applied. As aimed for, no hydrolysis product was found in cellular uptake experiments after 4 h whereas different metabolites were detected. Furthermore, the quercetin‐cinnamic acid amide showed pronounced activity in an in vivo AD mouse model at a remarkably low dose of 0.3 mg/kg.
- Top Cited Papers
- 24 May 2022
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 8 (6) , 2220-2231
Fibrin Sealants: Challenges and Solutions
Intraoperative bleeding and postoperative bleeding are major surgical complications. Tissue sealants, hemostats, and adhesives provide the armamentarium for establishing hemostatic balance, including the tissue sealant fibrin. Fibrin sealants combine advantages including instantaneous effect, biocompatibility, and biodegradability. However, several challenges remain. This review summarizes current fibrin product generations and highlights new trends and potential strategies for future improvement.
- 24 May 2022
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 8 (6) , 2220-2231
Top Cited PapersFibrin Sealants: Challenges and Solutions
Intraoperative bleeding and postoperative bleeding are major surgical complications. Tissue sealants, hemostats, and adhesives provide the armamentarium for establishing hemostatic balance, including the tissue sealant fibrin. Fibrin sealants combine advantages including instantaneous effect, biocompatibility, and biodegradability. However, several challenges remain. This review summarizes current fibrin product generations and highlights new trends and potential strategies for future improvement.